Related Experiment Videos
Kawasaki disease in Oman--a clinical study
Sunil Kumar Bhatnagar1, George Paul, Raghavan Subramanian
1Paediatric Infectious Diseases Unit, Division of Child Health, The Royal Hospital, Ministry of Health, Sultanate of Oman.
Insights
Kawasaki disease in Omani children presents with oral lesions and elevated inflammatory markers. Intravenous immunoglobulin and aspirin therapy proved safe and effective for treatment.
Area of Science:
- Pediatrics
- Rheumatology
- Epidemiology
Background:
- Kawasaki disease is a critical pediatric illness affecting medium-sized arteries.
- Understanding regional variations in Kawasaki disease presentation and outcomes is crucial for timely diagnosis and management.
Purpose of the Study:
- To describe the clinical and laboratory features of Kawasaki disease in Omani children.
- To evaluate the safety and efficacy of intravenous immunoglobulin and aspirin therapy in this population.
Main Methods:
- Retrospective analysis of 39 pediatric patients diagnosed with Kawasaki disease between 1995 and 2002.
- Review of case records for clinical manifestations, laboratory findings, and treatment outcomes.
Main Results:
- The peak age of onset was 6-30 months, with a mean age of 29 months.
- Oral lesions were present in all patients; elevated ESR and C-reactive protein were common.
- Echocardiographic abnormalities occurred in 25% of cases, with coronary artery involvement in 12.5%.
Conclusions:
- Kawasaki disease in Oman shares similarities with global presentations but highlights the importance of early diagnosis.
- Intravenous immunoglobulin and aspirin therapy demonstrated safety and effectiveness in this cohort.
Abstract:
A total of 39 patients were diagnosed to have Kawasaki disease by the standard diagnostic criteria, at The Royal Hospital, Muscat, Oman, during the period January 1995 to August 2002. A retrospective analysis of the case records of the patients with the diagnosis of Kawasaki disease was done. The results of the clinical features and the laboratory manifestations of the patients, who are from the Middle East region, are presented. The peak age at presentation was 6-30 months, mean 29 months. Peak months of the occurrence of the disease were March and October. Oral lesions were found in all cases. The mean duration of hospital stay for these patients was 8.5 days, range 2-21 days. The total duration of fever ranged from 6 to 21 days, with a mean value of 9.4 days. An elevated erythrocytic sedimentation rate (ESR; 91.7 per cent) and a raised C-reactive protein (C-RP; 92.3 per cent) were the most significant laboratory findings. Echocardiographic abnormalities were found in 25 per cent of cases, the incidence of coronary artery involvement (dilatation with or without stenosis) being 12.5 per cent. High dose intravenous immunoglobulin (2 g/kg over a 12-h period) plus aspirin therapy was found to be safe and effective in patients with Kawasaki disease.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Rheumatic Heart Disease III: Medical Management
Chronic Kidney Disease II: Clinical Manifestations